Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer
Comparison of topotecan weekly vs. topotecan day 1-5. The compatibility and activity are to be examined.
Ovarian Cancer
DRUG: Topotecan|DRUG: Topotecan
Rate of CR and PR in each arm, every 12 weeks
Toxicity of topotecan treatment, after each cycle|Progression-free survival of both arms, every 12 weeks
Topotecan belongs to the most effective medicaments in the therapy of relapsed platin-resistant ovarian cancer. Due to the low rate of hematological toxicities of grade 3 or 4 weekly application may be an improvement of therapy. None randomised study exists comparing a weekly topotecan application with an application on day 1-5. This study will compare the two applications in regard to: rate of complete or partial remissions, rate of toxicity, quality of life, progression free survival, overall survival.